Stocks · News reference

JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

Aug 7, 2026, 4:44 PMBenzinga Newsdesk

JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 7, 2026, 4:44 PM
Checked: Aug 7, 2026, 4:44 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 24, 2026, 12:02 PMBenzinga Newsdesk
Rhythm Pharmaceuticals Receives Marketing Authorization For IMCIVREE From Japan's Ministry Of Health To Treat Acquired Hypothalamic Obesity
Read original at benzinga
RYTM
BenzingaAug 12, 2026, 5:18 PMVandana Singh
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesity in adults and children 4 and older.
Read original at benzinga
RYTM
BenzingaAug 11, 2026, 12:03 PMBenzinga Newsdesk
Rhythm Pharmaceuticals Says UK MHRA Expands IMCIVREE Marketing Authorization To Acquired Hypothalamic Obesity In Patients 4 And Older, Grants Orphan Drug Designation
Read original at benzinga
RYTM